Call End: 09:01

Veru Inc. (NASDAQ:VERU)

Q2 2022 Earnings Conference Call

May 12, 2022 8:00 AM ET

Company Participants

Samuel Fisch - Executive Director, Investor Relations and Corporate Communications

Mitchell Steiner - Chairman, President and Chief Executive Officer

Michele Greco - Chief Financial Officer and Chief Administrative Officer

Gary Barnette - Chief Scientific Officer

Conference Call Participants

Brandon Folkes - Cantor Fitzgerald

Chris Howerton - Jefferies

Leland Gershell - Oppenheimer

Yi Chen - H.C. Wainwright

Kumar Raja - Brookline Capital Markets

Operator

Good morning, ladies and gentlemen, and welcome to Veru Incorporated Investor Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After this morning's discussion, there will be an opportunity to ask questions. Please note that this event is being recorded.

I would now like to turn the conference over to Mr. Sam Fisch, Veru Incorporated, Executive Director, Investor Relations and Corporate Communication. Please go ahead.

Samuel Fisch

Good morning. The statements made on this conference call may be forward-looking statements. Forward-looking statements may include but are not necessarily limited to, statements of the company's plans, objectives, expectations or intentions regarding its business, operations, finances and development and product portfolio. Such forward-looking statements are subject to known and unknown risks and uncertainties and our actual results may differ significantly from those projected, suggested or included in any forward-looking statements. Risks that may cause actual results or developments to differ materially are contained in our 10-Q and our 10-K SEC filings, as well as in our press releases from time to time.

I'd now like to turn the conference call over to Dr. Mitchell Steiner, Veru Inc's, Chairman, CEO and President.

Mitchell Steiner

Good morning. With me on this morning's call are Dr. Gary Barnette, Chief Scientific Officer; Michele Greco, the CFO and CAO; Michael Purvis, EVP, General Counsel and Corporate Strategy; and Sam Fisch, Executive Director of Investor Relations and Corporate Communications. Thank you for joining our call. Veru is a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS related diseases, and for the management of breast and prostate cancers.

The company has a commercial sexual health division called Urev, which includes two FDA approved products ENTADFI, a new treatment for benign prostatic hyperplasia and the FC2 female condom, internal condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The revenue from the sexual health division is being used to largely fund the clinical development of our late-stage drug candidate assets, which aim to address multi-billion dollar premium market opportunities.